- Jazz invested €50 million in the new facility.
- Construction began in February 2014.
- The facility has FDA and Irish regulatory approval.
- Up to 50 people will be employed within three years.
Facility Opening
Jazz Pharmaceuticals officially opened its new manufacturing and development facility in Monksland, Co. Roscommon, Ireland. The event was attended by key figures including the Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor, and the Global Head of Life Sciences of IDA Ireland, Barry Heavey.
Investment and Development
This is Jazz's first directly owned, managed, and operated manufacturing facility, representing an investment of approximately €50 million. The development began in February 2014 and was supported by IDA Ireland.
Regulatory Approval
The facility has secured full regulatory approval from the U.S. Food and Drug Administration (FDA) and the Health Products Regulatory Authority in Ireland.
Employment Impact
Jazz expects to employ up to 50 people within three years. The company currently employs around 100 people in Dublin and has operations in multiple U.S. cities, Oxford, England, and Villa Guardia, Italy.
Statements from Officials
Minister Mary Mitchell O’Connor highlighted the significance of the facility for the region, noting the job creation and economic benefits. Minister Denis Naughten emphasized the local talent and expertise, while Barry Heavey from IDA Ireland praised the strategic importance of the development for the pharmaceutical sector in regional locations.
